Impact of Diabetes and Metformin on Cardiovascular Outcomes in Prostate Cancer Patients Aged 66 and Older: The Role of Social Determinants of Health and Racial Disparities †
Authors:
- Priyanshu NainPriyanshu Nain
- Omar M. MakramOmar M. Makram
- Viraj ShahViraj Shah
- Harikrishnan Hyma KunhiramanHarikrishnan Hyma Kunhiraman
- Nickolas StabelliniNickolas Stabellini
- Biplab DattaBiplab Datta
- Stephanie JiangStephanie Jiang
- Vraj PatelVraj Patel
- Lakshya SethLakshya Seth
- Aditya BhaveAditya Bhave
- Sarah A. MalikSarah A. Malik
- Yan GongYan Gong
Open Access
Abstract
Background: This study evaluated the impact of diabetes mellitus (DM) and its treatments on cardiovascular outcomes in prostate cancer (PC) patients aged 66 years and older, with or without androgen deprivation therapy (ADT) exposure. Methods: Using the SEER-Medicare database (2009–2017), two cohorts were created: Cohort 1 included all PC patients enrolled in Medicare Parts A and B; Cohort 2 was a subset of Cohort 1 receiving ADT and enrolled in Medicare Part D. Exposures were DM and DM medications. Outcomes included cardiovascular events (CVEs), cardiovascular mortality (CVm), PC-specific mortality (PCsm), and all-cause mortality, analyzed using multivariable Fine-Gray and Cox models. Results: Cohort 1 included 150,647 PC patients (32% with DM, median age 72). DM was associated with higher risk of CVE (subdistribution hazard ratio [sHR] 1.20, 95% CI 1.17–1.22), CVm (sHR 1.35, 1.28–1.43), and all-cause mortality (adjusted HR [aHR] 1.22, 1.19–1.26) (all p < 0.001). Non-Hispanic Blacks (NHBs) and patients from lower socioeconomic (SES) and education areas experienced comparable or worse outcomes. In Cohort 2 (n = 14,938), DM patients on non-metformin therapies had higher all-cause mortality (aHR 1.33, 1.11–1.25; p = 0.002) than those on metformin, particularly in NHB and low education groups. Sensitivity analyses with follow-up limited to two years showed consistent results as overall. Conclusions: Diabetic PC patients, especially NHB, lower SES and lower education subgroups, were associated with worse cardiovascular and all-cause mortality outcomes. Metformin may be associated with better outcomes in these populations, warranting further research on the disparities in PC and diabetes, and cardioprotective effects of DM medications across different subpopulations.Keywords
This publication has 78 references indexed in Scilit:
- Understanding Cardiovascular Risk in Prostate Cancer: Role of Disparities, Diabetes, and AgingCurrent Treatment Options in Cardiovascular Medicine, 2024
- Diabetes mellitus in long‐term survivors with colorectal, breast, or prostate cancer: Prevalence and prognosis. A population‐based studyCancer, 2023
- Metformin use and mortality in Asian, diabetic patients with prostate cancer on androgen deprivation therapy: A population‐based studyThe Prostate, 2022
- Association of Gonadotropin-Releasing Hormone Agonists for Prostate Cancer With Cardiovascular Disease Risk and Hypertension in Men With DiabetesJAMA Network Open, 2022
- Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302European Journal of Cancer, 2022
- Association between baseline body mass index and survival in men with metastatic hormone‐sensitive prostate cancer: ECOG‐ACRIN CHAARTED E3805The Prostate, 2022
- TAXOMET: A French Prospective Multicentric Randomized Phase II Study of Docetaxel Plus Metformin Versus Docetaxel Plus Placebo in Metastatic Castration-Resistant Prostate CancerClinical Genitourinary Cancer, 2021
- Impact of Addition of Metformin to Abiraterone in Metastatic Castration-Resistant Prostate Cancer Patients With Disease Progressing While Receiving Abiraterone Treatment (MetAb-Pro): Phase 2 Pilot StudyClinical Genitourinary Cancer, 2019
- Outcomes of preexisting diabetes mellitus in breast, colorectal, and prostate cancerJournal of Cancer Survivorship, 2017
- Cardiovascular events associated with androgen deprivation therapy in patients with prostate cancer: a systematic review and meta-analysisWorld Journal of Urology, 2014